Inify Laboratories AB — Board/Management Information 2022

Jun 29, 2022

Inify Laboratories announces the appointment of Chief Medical Officer (CMO)

Inify Laboratories announces the appointment of Chief Medical Officer (CMO)

Stockholm, June 29th 2022

Inify Laboratories announces the addition of specialized medical competence to

the company's management team and organization.

"We warmly welcome Dr. Claes Lind to the role as CMO. His impressive background

in clinical diagnostics and education fits us perfectly. He will play an

instrumental role in our establishment and expansion phase. The fact that we can

attract such key competences to the company is a stamp of quality for our

strategy and concept," says Fredrik Palm.

Dr. Lindh will join Inify Laboratories in September 2022 as Chief Medical

Officer. He holds a M.D. as well as a Ph.D. in the field of prostate cancer

pathology from Karolinska Institute, and has 14 years of experience in

diagnostic pathology. He has worked as an expert pathologist in clinical

diagnostics, cancer research, and higher education. Before joining Inify

Laboratories, he acted as a senior consultant pathologist in Urological and

Gynecological pathology at Karolinska University Hospital. He has collaborated

in various translational research projects related to urological oncology. Dr

Lindh is also an experienced educator in pathology for bothmedical professionals

and students.

"The vision of Inify Laboratories- to take diagnostic pathology to a new level

by applying cutting-edge technology - represents an important milestone in the

history of pathology. Toparticipate in making the vision reality is truly

thrilling," says Dr. Claes Lindh.

"The CMO is a cornerstone recruitment for Inify, and a perfect match with our

targeted profile," says CEO Fredrik Palm.

Inify Laboratories is currently building and establishing an ultramodern

laboratory that will provide cancer diagnostics within histopathology. Designed

from scratch, it uses a fully digital, standardized and AI-supported workflow to

optimize quality and shorten response times, initially within prostate cancer.

The first laboratory, located at Campus Solna Sweden, is estimated to start

offering services to both public and private healthcare providers before summer

The company originates from ContextVision, with nearly 40 years of experience

within digital imaging for medical applications, and became independent through

a spin-off in February 2022.

The company, based in Sweden, is listed on Euronext Growth Oslo under the ticker

INIFY.

For more information, please contact CEO Fredrik Palm (fredrik.palm@inify.com)

or visit www.inify.com

This information is subject to the disclosure requirements pursuant to section 5

-12 of the Norwegian Securities Trading Act.